<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of differences of sex development</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of differences of sex development</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of differences of sex development</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yee-Ming Chan, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynne L Levitsky, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence S Baskin, MD, FAAP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1388369943"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Infants born with genitals that do not appear typically male or female or that have an appearance discordant with the chromosomal sex are classified as having a difference (or variation or disorder) of sex development (DSD). This term is not universally accepted by patients and is sometimes used to refer to a broad range of conditions including sex chromosome aneuploidies. In this topic review, we will use it to describe only those patients with a genital appearance that is atypical and/or discordant with chromosomal sex. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on 'Terminology'</a>.)</p><p>The vocabulary used to describe features of DSD can also be confusing and is sometimes inconsistently applied. A glossary of terms is provided  (<a class="graphic graphic_table graphicRef118023" href="/d/graphic/118023.html" rel="external">table 1</a>).</p><p>The causes of DSDs that present with atypical genital appearance are presented here, grouped by karyotype and mechanism. The evaluation and management of such infants are discussed separately. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a> and  <a class="medical medical_review" href="/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p class="headingAnchor" id="H1947572127"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>DSDs with genital abnormalities sufficient to prompt evaluation occur in approximately 1 in 1000 to 4500 live births [<a href="#rid1">1-3</a>]. The more common causes are:</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency in an XX individual</p><p class="bulletIndent1"><span class="glyph">●</span>Sex chromosome DSD with X/XY mosaicism</p><p class="bulletIndent1"><span class="glyph">●</span>Partial and complete androgen insensitivity syndrome (AIS) in an XY individual</p><p></p><p>Rarer causes include:</p><p class="bulletIndent1"><span class="glyph">●</span>In individuals with an XX karyotype:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CAH due to 11-beta-hydroxylase deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>CAH due to 3-beta-hydroxysteroid dehydrogenase (3-beta-HSD) deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>CAH due to P450 oxidoreductase (POR) deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>XX testicular/ovotesticular DSD due to <em>SRY</em> (sex-determining region on the Y chromosome) translocation or <em>NR5A1</em> gene mutation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In individuals with an XY karyotype:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>XY gonadal dysgenesis</p><p class="bulletIndent2"><span class="glyph">•</span>CAH due to 3-beta-HSD deficiency or POR deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>17-beta-hydroxysteroid dehydrogenase (17-beta-HSD) deficiency</p><p class="bulletIndent2"><span class="glyph">•</span>5-alpha reductase deficiency</p><p></p><p>These and some even rarer causes of DSDs are described below and outlined in the tables  (<a class="graphic graphic_table graphicRef56975" href="/d/graphic/56975.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef81145" href="/d/graphic/81145.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H2977549739"><span class="h1">CAUSES OF XX DIFFERENCES OF SEX DEVELOPMENT</span><span class="headingEndMark"> — </span>DSD in an individual with an XX complement of sex chromosomes is caused by atypically high levels of androgens, which can be due to overproduction of androgens by the adrenal cortex, overproduction by the gonads, or an ectopic or exogenous source of androgens. The genes implicated in XX DSD are summarized in the table  (<a class="graphic graphic_table graphicRef56975" href="/d/graphic/56975.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2347128032"><span class="h2">Adrenal overproduction of androgens</span><span class="headingEndMark"> — </span>Certain types of congenital adrenal hyperplasia (CAH) can cause overproduction of adrenal androgens and therefore lead to virilization in XX infants.</p><p>Measurement of serum 17-hydroxyprogesterone (17-OHP) identifies most XX infants with virilizing CAH because this metabolite is elevated in the most common type of CAH (21-hydroxylase deficiency), with lesser elevations in the other types of virilizing CAH (3-beta-hydroxysteroid dehydrogenase [3-beta-HSD] deficiency and 11-beta-hydroxylase deficiency). Concentrations of 17-hydroxypregnenolone, 11-deoxycortisol, and cortisol serve to distinguish among these various types of CAH  (<a class="graphic graphic_table graphicRef107536" href="/d/graphic/107536.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on 'Initial laboratory testing'</a> and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias"</a>.)</p><p class="headingAnchor" id="H1304894050"><span class="h3">Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency</span><span class="headingEndMark"> — </span>21-hydroxylase deficiency accounts for approximately 95 percent of CAH and is the most frequent cause of atypical genital appearance in general because the gene that encodes 21-hydroxylase (<em>CYP21A2</em>) is prone to mutation. 21-hydroxylase deficiency can be diagnosed based on elevated serum 17-OHP, one of the substrates for the enzyme  (<a class="graphic graphic_table graphicRef107536" href="/d/graphic/107536.html" rel="external">table 4</a>). In borderline cases, an adrenocorticotropic hormone (ACTH) stimulation test or genetic testing may be needed to establish the diagnosis. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on '17-hydroxyprogesterone'</a> and  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children", section on 'Additional testing for infants with equivocal results'</a>.)</p><p>Decreased activity of 21-hydroxylase results in decreased production of cortisol and aldosterone and overproduction of adrenal androgens (dehydroepiandrosterone [DHEA], androstenedione, and 11-ketotestosterone). Affected infants with 21-hydroxylase deficiency often have salt wasting, which causes hyponatremia with hyperkalemia, dehydration, and hypotension, and they are at risk for the life-threatening complication of adrenal crisis.</p><p class="headingAnchor" id="H3944166883"><span class="h3">Other types of congenital adrenal hyperplasia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>11-beta-hydroxylase deficiency</strong> (due to variants in the <em>CYP11B1</em> gene) is the second most common cause of CAH in the United States and Western Europe and is associated with significant elevation in 11-deoxycortisol and mild elevation in 17-OHP. As with 21-hydroxylase deficiency, there is overproduction of DHEA and androstenedione, and XX infants tend to have mildly to moderately virilized genitalia (clitoral enlargement, labial fusion). Salt wasting and adrenal crisis are rare. Both hypotension and hypertension have been reported in affected infants. Older children often manifest hypertension and <strong>hypo</strong>kalemia because of mineralocorticoid effects of elevated 11-deoxycortisol, which distinguish this condition from the hypotension and <strong>hyper</strong>kalemia that characterize 21-hydroxylase deficiency. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '11-beta-hydroxylase deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>3-beta-HSD type 2 deficiency</strong> (due to variants in the <em>HSD3B2</em> gene) is characterized by elevated 17-hydroxypregnenolone (not to be confused with 17-OHP) and an elevated ratio of 17-hydroxypregnenolone to cortisol [<a href="#rid4">4</a>]. Levels of 17-OHP are often moderately elevated as well; this apparently paradoxical elevation is due to the activity of another isoform of 3-beta-HSD that is encoded by a different gene (<em>HSD3B1</em>) and expressed in the liver, which can convert 17-hydroxypregnenolone to 17-OHP and DHEA to androstenedione, a relatively weak androgen.</p><p></p><p class="bulletIndent1">Affected XX individuals tend to have largely female-appearing external genitalia with relatively mild virilization (clitoromegaly). They tend to present as neonates or in early infancy with clinical manifestations of both cortisol and aldosterone deficiency, including vomiting, volume depletion, hyponatremia, and hyperkalemia. Of note, affected <strong>XY</strong> infants often show <strong>under</strong>virilization due to a block in testosterone synthesis, as noted below. (See <a class="local">'Forms of congenital adrenal hyperplasia'</a> below and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '3-beta-hydroxysteroid dehydrogenase type 2 deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P450 oxidoreductase</strong> <strong>(POR) deficiency</strong> (also known as apparent combined <em>CYP21A2</em> and <em>CYP17A1</em> deficiency due to variants in the <em>POR</em> gene) is a very rare cause of CAH. POR deficiency causes abnormal electron transport leading to decreased action of both 21-hydroxylase and 17-alpha hydroxylase, as well as aromatase.</p><p></p><p class="bulletIndent1">The phenotype is quite variable; XX individuals may be born with atypical genital appearance, and there can be maternal virilization during pregnancy due to decreased placental aromatase activity [<a href="#rid5">5,6</a>]. Some infants have craniofacial and limb abnormalities (also known as Antley-Bixler syndrome). Elevations in 17-OHP may be mild. Glucocorticoid deficiency is present to a variable degree, and patients are at risk for salt wasting and adrenal crisis. This condition can cause virilization in XX infants and undervirilization in XY infants (similar to 3-beta-HSD deficiency). (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a>.)</p><p></p><p class="headingAnchor" id="H581268589"><span class="h3">Glucocorticoid resistance</span><span class="headingEndMark"> — </span>Glucocorticoid resistance due to variants in the <em>NR3C1</em> gene that encodes the glucocorticoid receptor can cause features similar to those of virilizing forms of CAH, although it is not classified as a form of CAH, because cortisol synthesis is not disrupted. The impaired response to cortisol results in loss of negative feedback and high levels of ACTH, resulting in adrenal overproduction of mineralocorticoids (which can cause hypertension, hypokalemia, and alkalosis) and androgens (which can cause atypical genital appearance at birth or hyperandrogenism later in life in affected XX individuals). (See  <a class="medical medical_review" href="/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'End-organ unresponsiveness'</a>.)</p><p class="headingAnchor" id="H3839478987"><span class="h2">Gonadal overproduction of androgens</span></p><p class="headingAnchor" id="H333571857"><span class="h3">XX testicular and XX ovotesticular differences of sex development</span><span class="headingEndMark"> — </span>XX testicular DSD is a term for conditions in which the gonads develop along the testicular rather than the ovarian pathway. The resulting gonad may be either a largely normal or a dysgenetic testis. The consequent phenotype depends on the degree of production of testosterone and anti-müllerian hormone (AMH; also known as müllerian-inhibiting substance [MIS] and müllerian regression factor). Most causes of XX testicular DSD can also cause XX ovotesticular DSD, in which both ovarian follicular and testicular tubular tissue are present; the diagnosis is made based on histology, although the diagnosis can sometimes be suggested based on imaging and/or hormonal evaluation.</p><p>XX testicular or ovotesticular DSD is suggested by detection of testosterone (at baseline or after human chorionic gonadotropin [hCG] stimulation) and/or levels of AMH above the female reference range in an XX individual. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on 'Testosterone and other measures of gonadal function'</a>.)</p><p>Because an intact Y chromosome is required for spermatogenesis, XX testicular DSD is associated with inability to produce sperm. If there is intact ovarian tissue, oocyte maturation may be possible in some cases of XX ovotesticular DSD.</p><p>Causes of XX testicular or ovotesticular DSD include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presence of </strong><strong><em>SRY</em></strong> – This is due to translocation of <em>SRY</em> (sex-determining region on the Y chromosome) to the X chromosome or an autosome and accounts for roughly one-half of cases of XX testicular DSD. The presence of <em>SRY</em> results in activation of testicular pathways in the developing gonad.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variants in </strong><strong><em>NR5A1</em></strong> – The <em>NR5A1</em> (<em>SF1</em>) gene has long been known to play essential roles in initial gonadal development and in testicular differentiation; it is a well-known cause of XY DSD (see <a class="local">'XY gonadal dysgenesis'</a> below). In addition, heterozygous variants in <em>NR5A1</em> have been described in approximately 10 to 20 percent of cases of XX testicular or ovotesticular DSD [<a href="#rid7">7-10</a>]. Almost all of these variants affect a single amino acid residue, so it is possible that these are gain-of-function variants that cause inappropriate activation of testicular pathways in an XX gonad. Alternatively, <em>NR5A1</em> may play a role in suppressing testicular pathways during ovarian development (in addition to playing a role in promoting testicular pathways during testicular development).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duplication of </strong><strong><em>SOX9</em></strong> – The <em>SOX9</em> gene encodes a transcription factor that functions downstream of <em>SRY</em> and is both necessary and sufficient for testicular development. Duplications of the entire <em>SOX9</em> locus as well as of its upstream regulatory region have been described in individuals with XX testicular DSD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inappropriate expression of </strong><strong><em>SOX3</em></strong> – The <em>SOX3</em> gene encodes a transcription factor similar to <em>SOX9</em>. <em>SOX3</em> does not appear to have a role in normal gonadal development but appears to activate testicular pathways when inappropriately expressed (as can occur with duplications or variants in the <em>SOX3</em> regulatory region).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loss-of-function variants in genes that repress testicular</strong> <strong>pathways</strong> – Variants in these genes can cause XX testicular or ovotesticular DSD and are often associated with clinical abnormalities in nonreproductive organs:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>WNT4</em> gene variants are associated with the autosomal recessive SERKAL syndrome (sex reversal with dysgenesis of kidneys, adrenals, and lungs)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>RSPO1</em> gene variants are an autosomal recessive cause of palmoplantar hyperkeratosis in combination with testicular or ovotesticular DSD [<a href="#rid11">11,12</a>]</p><p></p><p class="headingAnchor" id="H3614761178"><span class="h3">Aromatase deficiency</span><span class="headingEndMark"> — </span>Aromatase deficiency (due to variants in the <em>CYP19A1</em> gene) can result in overproduction of testosterone by an otherwise normal ovary as the aromatase enzyme catalyzes the conversion of androgens to estrogens (eg, testosterone to estradiol) [<a href="#rid13">13</a>]. Because placental expression of aromatase is deficient, androgens from the fetus can cross the placenta and also cause maternal virilization. (See  <a class="medical medical_review" href="/d/html/7449.html" rel="external">"Gestational hyperandrogenism", section on 'Placental aromatase deficiency'</a>.)</p><p class="headingAnchor" id="H713626858"><span class="h2">Gestational hyperandrogenism</span><span class="headingEndMark"> — </span>Virilization in an XX individual with typical ovarian and adrenal function can result from exposure to maternal androgens or synthetic androgenic progestins. Because the placenta produces the aromatase enzyme, which converts androgens to estrogens, only very high levels of maternal androgens can overcome placental aromatase to cause virilization of the fetus. Causes include maternal luteoma or theca lutein cysts. These causes are suggested by a history of maternal virilization during pregnancy and/or exogenous exposure to androgens or an androgenic progestin [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/7449.html" rel="external">"Gestational hyperandrogenism"</a>.)</p><p class="headingAnchor" id="H836195097"><span class="h1">CAUSES OF XY DIFFERENCES OF SEX DEVELOPMENT</span><span class="headingEndMark"> — </span>XY DSDs occur because of atypically low levels of dihydrotestosterone action. This can be caused by a global defect in testicular function due to gonadal dysgenesis, a specific defect in androgen production, or an inability to respond to dihydrotestosterone and other androgens (androgen insensitivity). The genes implicated in XY DSD are summarized in the table  (<a class="graphic graphic_table graphicRef81145" href="/d/graphic/81145.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H1308367575"><span class="h2">Global defects in testicular function</span><span class="headingEndMark"> — </span>In these conditions, there are defects in both Leydig cell function, resulting in underproduction of testosterone, and Sertoli cell function, resulting in underproduction of anti-müllerian hormone (AMH) and inhibin B. Serum concentrations of AMH and inhibin B can be undetectable, detectable but below the male reference range, or within the male reference range, depending on the degree of the defect.</p><p>Because AMH secretion by the testes causes müllerian duct regression, decreased AMH secretion can result in fully or partially developed müllerian duct structures [<a href="#rid16">16,17</a>]. Low AMH concentration and/or persistence of müllerian structures in an XY individual suggests one of the following conditions, each of which is characterized by diminished testicular activity:</p><p class="headingAnchor" id="H3040695480"><span class="h3">XY gonadal dysgenesis</span><span class="headingEndMark"> — </span>Gonadal dysgenesis may be complete or partial. Complete XY gonadal dysgenesis (ie, complete failure of testicular development, also called Swyer syndrome) is associated with a typical female external genital appearance, intact müllerian structures, and streak gonads [<a href="#rid18">18</a>]. Partial gonadal dysgenesis can result in a wide range of testicular function and can in turn produce a similarly wide range of phenotypes, from isolated infertility without undervirilization, to hypospadias, to a frankly atypical genital appearance, to near-complete undervirilization with clitoromegaly. The müllerian structures may be normal, hypoplastic, or absent. By contrast, in XX individuals, gonadal dysgenesis does not interfere with genital development and therefore does not typically present with atypical genital appearance but may present with failure to enter puberty, primary amenorrhea, or secondary amenorrhea. (See  <a class="medical medical_review" href="/d/html/104218.html" rel="external">"Causes of primary amenorrhea"</a>.)</p><p>Gonadal dysgenesis and the presence of a Y chromosome creates a risk for gonadoblastoma. The risk varies depending on the condition and the degree of dysgenesis (with a lesser degree of dysgenesis associated with a lower risk). (See  <a class="medical medical_review" href="/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on 'Surgical decisions'</a>.)</p><p class="bulletIndent1">Specific causes of XY gonadal dysgenesis include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variants in </strong><strong><em>NR5A1</em></strong> – The <em>NR5A1</em> gene encodes steroidogenic factor 1, a transcription factor essential for development of the gonads and the adrenal cortex. Homozygous loss-of-function variants in <em>NR5A1</em> are rare and result in gonadal dysgenesis and adrenocortical insufficiency. Heterozygous loss-of-function variants in <em>NR5A1</em> account for approximately 10 to 15 percent of cases of testicular dysgenesis and are not usually associated with adrenal insufficiency. The degree of dysgenesis associated with heterozygous <em>NR5A1</em> variants ranges from minimal to complete, and other genes may contribute to this heterogeneity [<a href="#rid19">19</a>]. Some specific <em>NR5A1</em> variants may also cause testicular or ovotesticular DSD in an XX individual. (See <a class="local">'Gonadal overproduction of androgens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variants in </strong><strong><em>SRY</em></strong> – Decreased <em>SRY</em> (sex-determining region on the Y chromosome) function can result in complete or partial testicular dysgenesis, XY ovarian DSD, or XY ovotesticular DSD [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variants in </strong><strong><em>WT1</em></strong> – The <em>WT1</em> gene is involved in both renal development and gonadal development, and <em>WT1</em> variants are associated with a variety of conditions, some of which include partial or complete gonadal dysgenesis as a feature. Denys-Drash syndrome is associated with renal failure and high risk for Wilms tumor. Frasier syndrome is associated with nephrotic syndrome, usually due to focal segmental glomerulosclerosis, and particularly high risk for gonadoblastoma (around 50 percent lifetime incidence).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loss-of-function variants in genes essential for testicular development</strong> – These rare causes of XY gonadal dysgenesis are inherited in an autosomal recessive manner and include variants in the <em>MAP3K1</em>, <em>CBX2</em>, <em>DHH</em>, <em>DHX37</em>, <em>DMRT1</em>, <em>FGF9</em>, <em>FOG</em>, <em>GATA4</em>, <em>SOX9</em>, and <em>ZFPM2</em> genes. Some of these variants are associated with clinical abnormalities in nonreproductive organs (eg, campomelic dysplasia with variants in <em>SOX9</em>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gain-of-function variants in </strong><strong><em>NR0B1</em></strong> – Duplications of the <em>NR0B1</em> (<em>DAX1</em>) gene can cause gonadal dysgenesis, possibly by inhibiting activity of <em>NR5A1</em> (<em>SF1</em>). <em>NR0B1</em> does not appear to have a direct role in normal human gonadal development, because loss-of-function variants in <em>NR0B1</em> do not have a gonadal phenotype, although they do cause X-linked adrenal insufficiency and hypogonadotropic hypogonadism.</p><p></p><p>Y chromosome mosaicism can also cause gonadal dysgenesis. (See <a class="local">'Sex chromosome differences of sex development'</a> below.)</p><p class="headingAnchor" id="H3631648763"><span class="h3">XY ovarian differences of sex development</span><span class="headingEndMark"> — </span>In rare cases, the gonads in an XY individual may develop as ovaries. Loss-of-function variants in <em>SRY</em> [<a href="#rid21">21</a>], <em>CBX2</em> [<a href="#rid22">22</a>], and <em>NR5A1</em> [<a href="#rid23">23</a>] have been described as causes. Because cells have only one X chromosome, ovarian function in these cases would be expected to be reduced, similar to that of a girl with Turner syndrome (45,X karyotype).</p><p class="headingAnchor" id="H2164274830"><span class="h3">Testicular dysfunction without atypical genital appearance</span><span class="headingEndMark"> — </span>Other conditions that affect testicular function but <strong>do</strong> <strong>not</strong> usually present with atypical genital appearance include:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent müllerian duct syndrome – Persistent müllerian duct syndrome is caused by variants in the <em>AMH</em> gene, with low serum levels of AMH, or in the AMH receptor gene (<em>AMHR2</em>), with lack of response to AMH in an XY individual. The condition is characterized by a typical male external genital appearance, variable testicular descent, and presence of müllerian structures (such as a uterus) that may be discovered only incidentally [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testicular regression syndrome (also called congenital anorchia and previously referred to as vanishing testes syndrome) – Loss of testicular function later in fetal life results in anorchia but otherwise typical male genital appearance and absence of müllerian ducts (because of intact testicular function and production of dihydrotestosterone and AMH in early fetal development). The cause is often unclear but is thought to be due to bilateral fetal/infant testicular torsion in some cases. Variants in the <em>DHX37</em> gene have also been described as a cause of testicular regression syndrome as well as of XY gonadal dysgenesis, suggesting that some cases of testicular regression syndrome lie along a spectrum with XY gonadal dysgenesis [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H3224633943"><span class="h2">Conditions affecting androgen synthesis or response</span><span class="headingEndMark"> — </span>XY infants with reduced androgen synthesis or androgen sensitivity may demonstrate undervirilization but have typical AMH production (serum AMH in the typical male range and absence of müllerian structures). Testosterone measured at baseline or in response to human chorionic gonadotropin (hCG) may help to distinguish androgen underproduction from androgen insensitivity [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on 'Human chorionic gonadotropin stimulation test'</a>.)</p><p class="headingAnchor" id="H2072001356"><span class="h3">Reduced androgen synthesis</span><span class="headingEndMark"> — </span>Reduced androgen synthesis is suggested by low serum testosterone and/or dihydrotestosterone despite adequate stimulation by endogenous luteinizing hormone (LH; which is often elevated because of loss of negative feedback from sex steroids) or in response to exogenous hCG. This can occur due to conditions affecting signaling through the LH/CG receptor, synthesis of cholesterol (the substrate for steroid hormone synthesis), one of the many enzymatic steps for converting cholesterol to testosterone (some of which are also involved in adrenal hormone synthesis and can cause congenital adrenal hyperplasia [CAH]), or the conversion of testosterone to dihydrotestosterone.</p><p>These conditions, which are all autosomal recessive and rare, are:</p><p class="headingAnchor" id="H1132682090"><span class="h4">Leydig cell hypoplasia (LH/CG receptor defects)</span><span class="headingEndMark"> — </span>Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) share a common receptor, the LH/CG receptor, which is encoded by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F152790&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw%2Fgu0gA9BASBlnD2WO8d765&amp;TOPIC_ID=118045" target="_blank"><i>LHCGR</i></a> gene on chromosome 2p21 [<a href="#rid29">29,30</a>]. XY patients with variants in <em>LHCGR</em> characteristically have a typical female external genital appearance, though partial virilization is sometimes present, and lack a uterus and fallopian tubes; the epididymis and vas deferens may be present [<a href="#rid31">31,32</a>]. Laboratory evaluation reveals low testosterone concentrations despite an elevated concentration of LH (if assessed when the hypothalamic-pituitary-gonadal axis is active, ie, during the minipuberty of infancy or after puberty has started), and these children have absent or reduced responsiveness to exogenous hCG.</p><p class="headingAnchor" id="H2645698722"><span class="h4">Smith-Lemli-Opitz syndrome</span><span class="headingEndMark"> — </span>This autosomal recessive condition arises from a defect in the enzyme, sterol delta-7-reductase (encoded by the <em>DHCR7</em> gene), that catalyzes the last step in cholesterol synthesis. Affected individuals can exhibit growth and developmental delays, microcephaly, characteristic facial features, cleft palate, syndactyly and/or polydactyly, and other features, in addition to varying degrees of undervirilization. Diagnosis is made by finding an elevated serum level of 7-dehydrocholesterol and/or by genetic testing. The mechanism by which Smith-Lemli-Opitz syndrome causes these myriad phenotypes is unclear; possibilities include decreased production of steroid hormones (which all derive from cholesterol), impaired signal transduction through pathways that require cholesterol, and accumulation of toxic cholesterol-related metabolites.</p><p class="headingAnchor" id="H2403244563"><span class="h4">17-beta-hydroxysteroid dehydrogenase type 3 deficiency</span><span class="headingEndMark"> — </span>17-beta-hydroxysteroid dehydrogenase (17-beta-HSD) type 3 deficiency is caused by variants in the <em>HSD17B3</em> gene, which encodes an enzyme required for conversion of androstenedione to testosterone in the testes [<a href="#rid33">33</a>]. In this condition, serum testosterone concentrations are often in the lower normal range, whereas serum concentrations of androstenedione, the intermediate before the enzymatic block, are elevated several-fold  (<a class="graphic graphic_figure graphicRef65690" href="/d/graphic/65690.html" rel="external">figure 1</a>) [<a href="#rid34">34,35</a>]. The ratio of testosterone to androstenedione (when expressed in the same units) is usually less than 0.8, which distinguishes this condition from other forms of undervirilization, but, in some cases, there are no detectable hormonal abnormalities and the diagnosis is made only through genetic testing [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on 'Genetic testing'</a> and  <a class="medical medical_review" href="/d/html/7470.html" rel="external">"Steroid 5-alpha-reductase 2 deficiency", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H2565211725"><span class="h4">5-alpha-reductase type 2 deficiency</span><span class="headingEndMark"> — </span>In 5-alpha-reductase type 2 deficiency (due to variants in the <em>SRD5A2</em> gene), XY individuals with bilateral testes and normal testosterone synthesis have reduced external virilization during embryogenesis due to impaired conversion of testosterone to dihydrotestosterone [<a href="#rid37">37-39</a>]. In this condition, the ratio of testosterone:dihydrotestosterone (when expressed in the same units) is usually &gt;10:1. (See  <a class="medical medical_review" href="/d/html/7470.html" rel="external">"Steroid 5-alpha-reductase 2 deficiency"</a>.)</p><p class="headingAnchor" id="H97606714"><span class="h4">Forms of congenital adrenal hyperplasia</span><span class="headingEndMark"> — </span>Because many of the enzymes involved in cortisol synthesis are also involved in testosterone synthesis, several types of CAH can cause underproduction of testosterone and, in turn, undervirilization in an XY infant  (<a class="graphic graphic_table graphicRef107536" href="/d/graphic/107536.html" rel="external">table 4</a> and <a class="graphic graphic_figure graphicRef71558" href="/d/graphic/71558.html" rel="external">figure 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>3-beta-hydroxysteroid dehydrogenase type 2 deficiency (3-beta-HSD)</strong> – This condition is caused by variants in the <em>HSD3B2</em> gene; it causes variable undervirilization in XY individuals due to impaired conversion of dehydroepiandrosterone (DHEA) to androstenedione, the precursor to testosterone. Paradoxically, it can also cause mild virilization in XX individuals (as noted above) because of overproduction of DHEA, a weak androgen (see <a class="local">'Other types of congenital adrenal hyperplasia'</a> above). Affected individuals can have both cortisol and aldosterone deficiency, which may be life-threatening. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '3-beta-hydroxysteroid dehydrogenase type 2 deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>17-alpha-hydroxylase deficiency</strong> – This condition is caused by variants in the <em>CYP17A1</em> gene, which encodes a protein with both 17-alpha-hydroxylase and 17,20-lyase activities; it is characterized by undervirilization in XY individuals and may result in typical female external genital appearance. Most affected individuals have hypertension and <strong>hypo</strong>kalemia because of overproduction of mineralocorticoids; symptomatic adrenal insufficiency is rare. Partial deficiencies also occur and have milder phenotypes. Variants in <em>CYP17A1</em> that affect only 17,20-lyase activity are extremely rare and produce undervirilization without cortisol deficiency. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'CYP17A1 deficiencies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P450 oxidoreductase (POR) deficiency</strong> – This condition has features of 21-hydroxylase, 17-alpha hydroxylase, and aromatase deficiencies, and both XY and XX infants may be born with atypical genital appearance. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoid CAH</strong> – This condition is caused by deficiency of steroidogenic acute regulatory (StAR) protein; it is characterized by severe adrenal insufficiency very soon after birth, presenting with vomiting, diarrhea, volume depletion, hyponatremia, and hyperkalemia, often with hyperpigmentation. XY individuals have typical female external genital appearance. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P450 side-chain</strong> <strong>cleavage enzyme deficiency</strong> – This condition is caused by variants in the <em>CYP11A1</em> gene [<a href="#rid40">40</a>]. Similar to lipoid CAH, it is characterized by adrenal insufficiency and hyperpigmentation presenting in infancy or childhood, with typical female external genital appearance in XY individuals. (See  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Cholesterol side-chain cleavage enzyme (CYP11A1) deficiency'</a>.)</p><p></p><p>All of these forms of CAH except 17-alpha hydroxylase deficiency are usually associated with salt loss and may result in life-threatening adrenal crisis, so these conditions must be considered and diagnosed early. CAH caused by 21-hydroxylase deficiency does not result in atypical genital development in XY children but can result in adrenal crisis. This is a strong argument for neonatal CAH screening. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a>.)</p><p>If a form of CAH is identified, the infant may be at risk for adrenal crisis. It is sometimes necessary to evaluate adrenal function by performing an adrenocorticotropic hormone (ACTH) stimulation test to assess for glucocorticoid deficiency and excessive precursor accumulation. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on 'Adrenocorticotropic hormone stimulation test'</a>.)</p><p class="headingAnchor" id="H3496676800"><span class="h3">Androgen insensitivity</span><span class="headingEndMark"> — </span>In an individual with XY DSD, normal or elevated serum testosterone production at baseline or after hCG stimulation suggests androgen insensitivity syndrome (AIS), which is caused by variants in the androgen receptor (<em>AR</em>) gene. Patients with complete AIS (CAIS) have a typical female external genital appearance. Patients with partial AIS (PAIS) present with a range of phenotypes, from predominantly female genital appearance with mild virilization, to more atypical genital appearance, to typical male genital appearance with infertility. (See  <a class="medical medical_review" href="/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor"</a>.)</p><p>The diagnosis of AIS (CAIS or PAIS) can be definitively established with <em>AR</em> gene sequencing (whether through single-gene sequencing or as part of a gene panel or exome/genome sequencing) or fibroblast AR kinetics (not widely available). Gene panels and exome/genome sequencing have the advantage of potentially detecting other causes of XY undervirilization such as gonadal dysgenesis due to an <em>NR5A1</em>/<em>SF-1</em> gene variant or impaired testosterone biosynthesis due to 17-beta-HSD deficiency, which may have clinical presentations similar to that of PAIS. Of note, responses to hCG may be attenuated in patients with androgen insensitivity for reasons that are unclear [<a href="#rid41">41</a>].</p><p>Management of this condition is discussed separately. (See  <a class="medical medical_review" href="/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on 'Partial androgen insensitivity syndrome'</a> and  <a class="medical medical_review" href="/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor"</a>.)</p><p class="headingAnchor" id="H4068819155"><span class="h2">Other causes of XY differences of sex development</span><span class="headingEndMark"> — </span>Occasionally, boys with hypospadias or even a more atypical genital appearance may have histories of in utero exposure to "endocrine disrupters." <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">Phenytoin</a> and <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a>, as well as environmental exposures, have been implicated, but the relationship of putative endocrine disruptors to hypospadias is still unclear [<a href="#rid42">42,43</a>]. Children whose DSD was caused by in utero exposure to endocrine disrupters should have normal physiologic and anatomic responses to sex steroids as well as to gonadotropin stimuli after birth. (See  <a class="medical medical_review" href="/d/html/6583.html" rel="external">"Hypospadias: Pathogenesis, diagnosis, and evaluation", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H3905850358"><span class="h1">SEX CHROMOSOME DIFFERENCES OF SEX DEVELOPMENT</span><span class="headingEndMark"> — </span>This subtype of DSD is defined by presence of a sex chromosome complement other than XX or XY. It includes conditions with mosaicism or chimerism resulting in the presence of the Y chromosome in some cells but not others, which may (or may not) result in an atypical genital appearance.</p><p>The term "sex chromosome DSD" is sometimes used to include karyotypes that do not result in atypical genital development, such as 45,X (Turner syndrome) and 47,XXY (Klinefelter syndrome). (See  <a class="medical medical_review" href="/d/html/7391.html" rel="external">"Clinical manifestations and diagnosis of Turner syndrome"</a> and  <a class="medical medical_review" href="/d/html/13921.html" rel="external">"Clinical features, diagnosis, and management of Klinefelter syndrome"</a>.)</p><p>Mosaicism arises postzygotically due to the improper segregation of chromosomes during mitosis. The most common karyotype with mosaicism of the Y chromosome is 45,X/46,XY, but other combinations are possible (eg, 45,X/47,XXY; 46,XX/47,XXY). Chimerism results from the fusion of two zygotes; if the zygotes have different chromosomal sexes, the resulting chimera has a 46,XX/46,XY karyotype.</p><p>Y chromosome mosaicism/chimerism can result in a broad range of reproductive phenotypes. Each gonad can develop as:</p><p class="bulletIndent1"><span class="glyph">●</span>A normal or dysgenetic testis</p><p class="bulletIndent1"><span class="glyph">●</span>A normal or dysgenetic ovary</p><p class="bulletIndent1"><span class="glyph">●</span>A streak gonad (a gonad that is so dysgenetic that it is not readily recognizable as a testis or ovary)</p><p class="bulletIndent1"><span class="glyph">●</span>An ovotestis (very rare)</p><p></p><p>Also, the two gonads may develop differently. "Mixed gonadal dysgenesis" refers to asymmetric gonadal development with one gonad being dysgenetic. For unknown reasons, the right gonad is more likely to develop into a dysgenetic testis and the left gonad is more likely to be a streak gonad or an ovary. While the term "mixed gonadal dysgenesis" technically describes a gonadal phenotype, many use the term synonymously with a 45,X/46,XY karyotype resulting in atypical gonadal development.</p><p>The identity of each gonad in turn influences the development of the ipsilateral internal and external reproductive structures. Most individuals with a 45,X/46,XY karyotype have sufficient bilateral testicular development and function to lead to a typical male appearance of the external genitalia. For those who have mixed gonadal dysgenesis, a typical phenotype involves having a dysgenetic testicle, Wolffian structures, and a hemiscrotum on one side (usually the right) and a gonadal streak, müllerian structures (often incompletely developed), and an empty and underdeveloped labioscrotal fold on the other, producing asymmetric genital anatomy  (<a class="graphic graphic_picture graphicRef60214" href="/d/graphic/60214.html" rel="external">picture 1</a> and <a class="graphic graphic_diagnosticimage graphicRef106091" href="/d/graphic/106091.html" rel="external">image 1</a>). Individuals with mixed gonadal dysgenesis have variable degrees of atypical genital appearance. The presence of any external genital asymmetry should raise suspicion of this condition. However, both the degree of mosaicism and phenotype can be quite variable, with the phenotype ranging from typical male to typical female external genital appearance, potentially associated with somatic features of Turner syndrome. (See  <a class="medical medical_review" href="/d/html/7391.html" rel="external">"Clinical manifestations and diagnosis of Turner syndrome"</a>.)</p><p>Patients with any of the above forms of Y chromosome mosaicism/chimerism and a dysgenetic gonad have an increased risk for gonadoblastoma, similar to patients with complete XY gonadal dysgenesis (Swyer syndrome). The risk is lower if the gonads are in the scrotum and higher if they are in the abdomen. Management of this risk, including consideration of gonadectomy, is discussed separately. (See  <a class="medical medical_review" href="/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on 'Gonads'</a>.)</p><p>The underlying karyotype can cause other associated features. For instance, individuals with a 45,X/46,XY karyotype may have features of Turner syndrome and individuals with a 46,XX/47,XXY karyotype may have features of Klinefelter syndrome. Male fertility requires testicular tissue and an intact Y chromosome, and female fertility generally requires two X chromosomes in addition to ovarian tissue.</p><p class="headingAnchor" id="H3843181680"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112671.html" rel="external">"Society guideline links: Classic and nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113605.html" rel="external">"Society guideline links: Differences of sex development"</a>.)</p><p class="headingAnchor" id="H3499448469"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Infants born with a genital appearance that is neither typically male nor female or that have an appearance discordant with the chromosomal sex are classified as having a difference (or variation) of sex development (DSD). The vocabulary used to describe features of DSD can also be confusing and is sometimes inconsistently applied. A glossary of terms is provided  (<a class="graphic graphic_table graphicRef118023" href="/d/graphic/118023.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)", section on 'Terminology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes in 46,XX individuals</strong> – Causes of atypical genital appearance in 46,XX individuals include  (<a class="graphic graphic_table graphicRef56975" href="/d/graphic/56975.html" rel="external">table 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Classic congenital adrenal hyperplasia (CAH)</strong> – The most common cause of an atypical genital appearance is classic CAH due to 21-hydroxylase deficiency, which causes virilization in individuals with an XX karyotype. Prompt recognition (through newborn screening in all of the United States and in many Western countries) and treatment are important to avoid the possibility of early adrenal crisis; the condition is diagnosed by detecting marked elevations in 17-hydroxyprogesterone (17-OHP). (See <a class="local">'Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Less common causes of CAH (eg, 11-beta-hydroxylase deficiency and 3-beta-hydroxysteroid dehydrogenase deficiency [3-beta-HSD]) (see <a class="local">'Other types of congenital adrenal hyperplasia'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Testicular DSD and ovotesticular DSD (resulting in gonadal production of androgens) (see <a class="local">'Gonadal overproduction of androgens'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Rarely, gestational hyperandrogenism due to exposure to maternal androgen or synthetic androgenic progestins (see <a class="local">'Gestational hyperandrogenism'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes in XY individuals</strong> – Causes of an atypical genital appearance in XY individuals include  (<a class="graphic graphic_table graphicRef81145" href="/d/graphic/81145.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gonadal dysgenesis leading to global defects in testicular function, with underproduction of testosterone, anti-müllerian hormone (AMH; also known as müllerian-inhibiting substance [MIS] and müllerian regression factor) and inhibin B (see <a class="local">'Global defects in testicular function'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conditions with reduced androgen synthesis, including defects in the luteinizing hormone/human chorionic gonadotropin (LH/hCG) receptor and defects in several enzymes required for androgen synthesis  (<a class="graphic graphic_figure graphicRef65690" href="/d/graphic/65690.html" rel="external">figure 1</a>); these include several uncommon forms of CAH  (<a class="graphic graphic_table graphicRef107536" href="/d/graphic/107536.html" rel="external">table 4</a>) (see <a class="local">'Reduced androgen synthesis'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Androgen insensitivity syndrome (AIS) due to reduced function of the androgen receptor (AR) (see <a class="local">'Androgen insensitivity'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex chromosome DSD</strong> – Mosaicism or chimerism affecting the Y chromosome can result in a wide range of gonadal phenotypes, including mixed gonadal dysgenesis (gonads that develop differently from each other, with varying degrees of dysgenesis), normal or dysgenetic testes or ovaries, streak gonads, or ovotestes. (See <a class="local">'Sex chromosome differences of sex development'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gonadoblastoma risk</strong> – Patients with a Y chromosome and a dysgenetic gonad have an increased risk for gonadoblastoma. (See <a class="local">'Sex chromosome differences of sex development'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT. Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development. Best Pract Res Clin Endocrinol Metab 2007; 21:351.</a></li><li><a class="nounderline abstract_t">Blackless M, Charuvastra A, Derryck A, et al. How sexually dimorphic are we? Review and synthesis. Am J Hum Biol 2000; 12:151.</a></li><li><a class="nounderline abstract_t">Thyen U, Lanz K, Holterhus PM, Hiort O. Epidemiology and initial management of ambiguous genitalia at birth in Germany. Horm Res 2006; 66:195.</a></li><li><a class="nounderline abstract_t">Tordjman K, Jaffe A, Trostanetsky Y, et al. Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf) 2000; 52:633.</a></li><li><a class="nounderline abstract_t">Flück CE, Miller WL. P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia. Curr Opin Pediatr 2006; 18:435.</a></li><li><a class="nounderline abstract_t">Dean B, Chrisp GL, Quartararo M, et al. P450 Oxidoreductase Deficiency: A Systematic Review and Meta-analysis of Genotypes, Phenotypes, and Their Relationships. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Bashamboo A, Donohoue PA, Vilain E, et al. A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development. Hum Mol Genet 2016; 25:3446.</a></li><li><a class="nounderline abstract_t">Baetens D, Stoop H, Peelman F, et al. NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development. Genet Med 2017; 19:367.</a></li><li><a class="nounderline abstract_t">Igarashi M, Takasawa K, Hakoda A, et al. Identical NR5A1 Missense Mutations in Two Unrelated 46,XX Individuals with Testicular Tissues. Hum Mutat 2017; 38:39.</a></li><li><a class="nounderline abstract_t">Swartz JM, Ciarlo R, Guo MH, et al. A 46,XX Ovotesticular Disorder of Sex Development Likely Caused by a Steroidogenic Factor-1 (NR5A1) Variant. Horm Res Paediatr 2017; 87:191.</a></li><li><a class="nounderline abstract_t">Tomaselli S, Megiorni F, De Bernardo C, et al. Syndromic true hermaphroditism due to an R-spondin1 (RSPO1) homozygous mutation. Hum Mutat 2008; 29:220.</a></li><li><a class="nounderline abstract_t">Parma P, Radi O, Vidal V, et al. R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat Genet 2006; 38:1304.</a></li><li><a class="nounderline abstract_t">Fan L, Zhang B, Li L, Gong C. Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature. Clin Endocrinol (Oxf) 2020; 93:687.</a></li><li><a class="nounderline abstract_t">Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999; 84:4677.</a></li><li><a class="nounderline abstract_t">Hougen HY, Seideman CA, Adam MP, et al. Congenital virilization of female infants recognized after pregnancies with retained levonorgestrel intrauterine devices. J Pediatr Urol 2020; 16:241.</a></li><li><a class="nounderline abstract_t">Lee MM, Donahoe PK, Silverman BL, et al. Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997; 336:1480.</a></li><li><a class="nounderline abstract_t">Rey RA, Belville C, Nihoul-Fékété C, et al. Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab 1999; 84:627.</a></li><li><a class="nounderline abstract_t">Schnitzer JJ, Donahoe PK. Surgical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:137.</a></li><li><a class="nounderline abstract_t">Kouri C, Sommer G, Flück CE. Oligogenic Causes of Human Differences of Sex Development: Facing the Challenge of Genetic Complexity. Horm Res Paediatr 2023; 96:169.</a></li><li><a class="nounderline abstract_t">Ürel Demir G, Doğan ÖA, Şimşek Kiper PÖ, et al. Coexistence of Trisomy 13 and SRY (-) XX Ovotesticular Disorder of Sex Development. Fetal Pediatr Pathol 2017; 36:445.</a></li><li><a class="nounderline abstract_t">Stoppa-Vaucher S, Ayabe T, Paquette J, et al. 46, XY gonadal dysgenesis: new SRY point mutation in two siblings with paternal germ line mosaicism. Clin Genet 2012; 82:505.</a></li><li><a class="nounderline abstract_t">Biason-Lauber A, Konrad D, Meyer M, et al. Ovaries and female phenotype in a girl with 46,XY karyotype and mutations in the CBX2 gene. Am J Hum Genet 2009; 84:658.</a></li><li><a class="nounderline abstract_t">Biason-Lauber A, Schoenle EJ. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 2000; 67:1563.</a></li><li><a class="nounderline abstract_t">Knebelmann B, Boussin L, Guerrier D, et al. Anti-Müllerian hormone Bruxelles: a nonsense mutation associated with the persistent Müllerian duct syndrome. Proc Natl Acad Sci U S A 1991; 88:3767.</a></li><li><a class="nounderline abstract_t">Imbeaud S, Carré-Eusèbe D, Rey R, et al. Molecular genetics of the persistent müllerian duct syndrome: a study of 19 families. Hum Mol Genet 1994; 3:125.</a></li><li><a class="nounderline abstract_t">Imbeaud S, Belville C, Messika-Zeitoun L, et al. A 27 base-pair deletion of the anti-müllerian type II receptor gene is the most common cause of the persistent müllerian duct syndrome. Hum Mol Genet 1996; 5:1269.</a></li><li><a class="nounderline abstract_t">McElreavey K, Jorgensen A, Eozenou C, et al. Pathogenic variants in the DEAH-box RNA helicase DHX37 are a frequent cause of 46,XY gonadal dysgenesis and 46,XY testicular regression syndrome. Genet Med 2020; 22:150.</a></li><li><a class="nounderline abstract_t">Forest MG. Pattern of the response of testosterone and its precursors to human chorionic gonadotropin stimulation in relation to age in infants and children. J Clin Endocrinol Metab 1979; 49:132.</a></li><li><a class="nounderline abstract_t">Latronico AC, Anasti J, Arnhold IJ, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996; 334:507.</a></li><li><a class="nounderline abstract_t">Rousseau-Merck MF, Misrahi M, Atger M, et al. Localization of the human luteinizing hormone/choriogonadotropin receptor gene (LHCGR) to chromosome 2p21. Cytogenet Cell Genet 1990; 54:77.</a></li><li><a class="nounderline abstract_t">Berthezène F, Forest MG, Grimaud JA, et al. Leydig-cell agenesis: a cause of male pseudohermaphroditism. N Engl J Med 1976; 295:969.</a></li><li><a class="nounderline abstract_t">Pérez-Palacios G, Scaglia HE, Kofman-Alfaro S, et al. Inherited male pseudohermaphroditism due to gonadotrophin unresponsiveness. Acta Endocrinol (Copenh) 1981; 98:148.</a></li><li><a class="nounderline abstract_t">Andersson S, Moghrabi N. Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases. Steroids 1997; 62:143.</a></li><li><a class="nounderline abstract_t">Givens JR, Wiser WL, Summitt RL, et al. Familial male pseudohermaphroditism without gynecomastia due to deficient testicular 17-ketosteroid reductase activity. N Engl J Med 1974; 291:938.</a></li><li><a class="nounderline abstract_t">Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 2000; 79:299.</a></li><li><a class="nounderline abstract_t">Faisal Ahmed S, Iqbal A, Hughes IA. The testosterone:androstenedione ratio in male undermasculinization. Clin Endocrinol (Oxf) 2000; 53:697.</a></li><li><a class="nounderline abstract_t">Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291:944.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Gautier T, Pichardo M, Shackleton C. The diagnosis of 5 alpha-reductase deficiency in infancy. J Clin Endocrinol Metab 1986; 63:1313.</a></li><li><a class="nounderline abstract_t">Kim CJ, Lin L, Huang N, et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab 2008; 93:696.</a></li><li><a class="nounderline abstract_t">Ahmed SF, Cheng A, Hughes IA. Assessment of the gonadotrophin-gonadal axis in androgen insensitivity syndrome. Arch Dis Child 1999; 80:324.</a></li><li><a class="nounderline abstract_t">Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ, et al. Association of prenatal phenobarbital and phenytoin exposure with genital anomalies and menstrual disorders. Teratology 2001; 64:181.</a></li><li><a class="nounderline abstract_t">Yiee JH, Baskin LS. Environmental factors in genitourinary development. J Urol 2010; 184:34.</a></li></ol></div><div id="topicVersionRevision">Topic 118045 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875484" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11534012" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : How sexually dimorphic are we? Review and synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877870" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology and initial management of ambiguous genitalia at birth in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792344" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16915000" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825489" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : P450 Oxidoreductase Deficiency: A Systematic Review and Meta-analysis of Genotypes, Phenotypes, and Their Relationships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27378692" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27490115" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27610946" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identical NR5A1 Missense Mutations in Two Unrelated 46,XX Individuals with Testicular Tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27855412" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A 46,XX Ovotesticular Disorder of Sex Development Likely Caused by a Steroidogenic Factor-1 (NR5A1) Variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18085567" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Syndromic true hermaphroditism due to an R-spondin1 (RSPO1) homozygous mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17041600" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : R-spondin1 is essential in sex determination, skin differentiation and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32623730" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10599737" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Estrogen: consequences and implications of human mutations in synthesis and action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32265103" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Congenital virilization of female infants recognized after pregnancies with retained levonorgestrel intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154766" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022428" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344932" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Surgical treatment of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34537773" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Oligogenic Causes of Human Differences of Sex Development: Facing the Challenge of Genetic Complexity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29220612" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Coexistence of Trisomy 13 and SRY (-) XX Ovotesticular Disorder of Sex Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22288726" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 46, XY gonadal dysgenesis: new SRY point mutation in two siblings with paternal germ line mosaicism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19361780" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ovaries and female phenotype in a girl with 46,XY karyotype and mutations in the CBX2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038323" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2023927" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anti-Müllerian hormone Bruxelles: a nonsense mutation associated with the persistent Müllerian duct syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162013" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular genetics of the persistent müllerian duct syndrome: a study of 19 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8872466" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A 27 base-pair deletion of the anti-müllerian type II receptor gene is the most common cause of the persistent müllerian duct syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31337883" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pathogenic variants in the DEAH-box RNA helicase DHX37 are a frequent cause of 46,XY gonadal dysgenesis and 46,XY testicular regression syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/447811" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pattern of the response of testosterone and its precursors to human chorionic gonadotropin stimulation in relation to age in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559204" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2249480" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Localization of the human luteinizing hormone/choriogonadotropin receptor gene (LHCGR) to chromosome 2p21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/184390" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Leydig-cell agenesis: a cause of male pseudohermaphroditism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6792847" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inherited male pseudohermaphroditism due to gonadotrophin unresponsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9029729" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4278097" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Familial male pseudohermaphroditism without gynecomastia due to deficient testicular 17-ketosteroid reductase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11039078" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11155091" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The testosterone:androstenedione ratio in male undermasculinization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4413434" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4432067" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3782419" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The diagnosis of 5 alpha-reductase deficiency in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182448" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086936" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of the gonadotrophin-gonadal axis in androgen insensitivity syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598924" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of prenatal phenobarbital and phenytoin exposure with genital anomalies and menstrual disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478588" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Environmental factors in genitourinary development.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
